Redeye raises its Base case to SEK220 (200) per share following the orphan drug designation (ODD) for HyNap-Nilo and positive data with improved HyNap-Dasa. From an investor's point-of-view, it's encouraging to see progress in the pipeline beyond generic HyNap-Dasa, which reignites focus on the platform story.